

# Ilaria Maccora

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/678489/publications.pdf>

Version: 2024-02-01

46  
papers

300  
citations

1040018

9  
h-index

996954

15  
g-index

49  
all docs

49  
docs citations

49  
times ranked

319  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in Pregnant Women and Neonates: A Systematic Review of the Literature with Quality Assessment of the Studies. <i>Pathogens</i> , 2020, 9, 485.	2.8	62
2	Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. <i>Rheumatology</i> , 2021, 60, 568-587.	1.9	26
3	Update on noninfectious uveitis in children and its treatment. <i>Current Opinion in Rheumatology</i> , 2020, 32, 395-402.	4.3	25
4	The off-label use of anakinra in pediatric systemic autoinflammatory diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2095957.	2.7	17
5	Ocular involvement in monogenic autoinflammatory disease. <i>Autoimmunity Reviews</i> , 2021, 20, 102944.	5.8	17
6	New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritisâ€“Associated Uveitis and Idiopathic Chronic Anterior Uveitis. <i>Arthritis Care and Research</i> , 2023, 75, 975-982.	3.4	17
7	The Influence of Overweight and Obesity on Treatment Response in Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2019, 10, 637.	3.5	16
8	Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment. <i>Critical Care</i> , 2021, 25, 131.	5.8	12
9	Safety evaluations of adalimumab for childhood chronic rheumatic diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 661-671.	2.4	11
10	The Role of Anti-IL-1 Treatment in MIS-C Patients. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1-5.	3.1	9
11	A misleading case of deficiency of adenosine deaminase 2 (DADA2): the magnifying glass of the scientific knowledge drives the tailored medicine in real life. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 146.	0.8	9
12	A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 457-470.	0.8	9
13	Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience. <i>Frontiers in Pediatrics</i> , 2022, 10, 851453.	1.9	9
14	OBSIDIAN â€“ real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2022, 61, 1518-1528.	1.9	8
15	The Development of Extra-Articular Manifestations in Children With Enthesitis-Related Arthritis: Natural Course or Different Disease Entity?. <i>Frontiers in Medicine</i> , 2021, 8, 667305.	2.6	7
16	Long-term follow-up of coronary artery lesions in children in Kawasaki syndrome. <i>European Journal of Pediatrics</i> , 2021, 180, 271-275.	2.7	6
17	Moving from nature to nurture: a systematic review and meta-analysis of environmental factors associated with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2022, 61, 514-530.	1.9	6
18	Common variable immunodeficiency presenting as sarcoidosis in a 9â€“yearâ€“old child. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 448-453.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Early anti IL-1 treatment replaces steroids in refractory Kawasaki disease: clinical experience from two case reports. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110025.	2.7	4
20	Sideroblastic anaemia, immunodeficiency, periodic fevers and developmental delay (SIFD) presenting as systemic inflammation with arthritis. <i>Rheumatology</i> , 2021, 60, e234-e236.	1.9	4
21	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis. <i>Scientific Reports</i> , 2021, 11, 16393.	3.3	3
22	Adherence to guideline recommendations in the management of pediatric cardiac arrest: a multicentre observational simulation-based study. <i>European Journal of Emergency Medicine</i> , 2022, 29, 271-278.	1.1	3
23	Diagnostic challenge of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome in pediatric age: A monocentric case series. <i>Modern Rheumatology</i> , 2021, 31, 1228-1231.	1.8	2
24	Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 290.	0.8	2
25	Behçet syndrome in children and adults: discovering similarities and differences by a comparative study. <i>Rheumatology</i> , 2023, 62, SI189-SI195.	1.9	2
26	Mycophenolate mofetil-induced hypogammaglobulinemia and infectious disease susceptibility in pediatric patients with chronic rheumatic disorders: a monocentric retrospective study. <i>European Journal of Pediatrics</i> , 2022, 181, 3439-3448.	2.7	2
27	Is Echocardiography Critical in Patients With Kawasaki Disease With a z Score Less Than 2 to 6 Weeks From Onset?. <i>JAMA Pediatrics</i> , 2019, 173, 700.	6.2	1
28	Too young to fail: a case report on the effectiveness of tocilizumab for paediatric systemic sclerosis-associated interstitial lung disease. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 1-2.	1.1	1
29	Cervical arthritis as early manifestation of enthesitis-related arthritis complicated by uveitis. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 1531-1532.	0.8	1
30	Cerebral venous thrombosis in a child with Behçet's disease: a complication to bear in mind also in children. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 141-142.	0.8	1
31	Biological drugs in paediatric COVID-19 infection: what patients, which drug, how much and how long. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 697-699.	0.8	1
32	SAT0513â€¦Brainstem Auditory Evoked Potentials and Visual Potentials in Kawasaki Disease: Expression of CNS Vasculitis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 846.1-846.	0.9	0
33	Learning Disability in RASopathies. , 2017, , .		0
34	AB1012â€¦HENOCH-SCHÖNLEIN PURPURA AND UVEITIS, AN UNUSUAL ASSOCIATION. , 2019, , .		0
35	AB1015â€¦CENTRAL NERVOUS SYSTEM VASCULITIS PRECEDING. , 2019, , .		0
36	SAT0505â€¦LONG-TERM FOLLOW-UP IN KAWASAKI SYNDROME: EVIDENCE FROM RETROSPECTIVE MONOCENTRIC DATA IN REAL LIFE. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	Systemic Immunomodulatory Therapy in Pediatric Uveitis. <i>Advances in Ophthalmology and Optometry</i> , 2021, 6, 87-100.	0.3	0
38	Joint pain management in children and adolescents. <i>Minerva Pediatrics</i> , 2018, 70, 79-97.	0.4	0
39	AB0989â€¦TUBERCULOSIS RISK IN CHILDREN WITH RHEUMATIC DISEASES TREATED WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1788-1789.	0.9	0
40	Reply letter to letter to the editor. <i>Autoimmunity Reviews</i> , 2022, , 103059.	5.8	0
41	Uveitis and Henoch-SchÅ¶nlein purpura: case report and literature review. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 238.	0.8	0
42	Successful treatment of adalimumab in a child with Vogt-Koyanagi-Harada: which is the best available systemic treatment?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1453-1454.	0.8	0
43	Cerebral venous thrombosis in a child with BehÅ¶set's disease: a complication to bear in mind also in children. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 141-142.	0.8	0
44	A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine.. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
45	Autoimmune uveitis in childhood. , 2022, , 121-137.		0
46	<i>Comment on:</i> Distal coronary artery abnormalities in Kawasaki disease: experience on CT coronary angiography in 176 children. <i>Rheumatology</i> , 0, , .	1.9	0